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Off targets toxicological investigation of anti-cancer tubulin inhibitors
Abboud Sabbagh, Yaxin Li, Bin Su
Department of Chemistry, College of Sciences and Health Professions, Cleveland State University

ABSTRACT

METHODS

A class of novel tubulin inhibitors was synthesized based on NSC751382
(Figure 1), Benzo[1,3]dioxole-5-carboxylic acid [3-(2,5-dimethylbenzyloxy)-4-(methanesulfonyl-methyl-amino)-phenyl] -amide, as the
lead compound. This compound showed potent tubulin polymerization
inhibitory activity by binding at the colchicine's binding domain, and
suppressed cancer cell growth with an IC50 of 200 nM. It has a molecular
weight of 482 g/mol, logP of 4.1, only one hydrogen bond donor, and
eight hydrogen bond acceptors. The compound meets the Lipinski's Rule
of Five and is a highly drug-like molecule. In addition, NSC751382
significantly inhibited the growth of Taxol resistant cancer cells,
suggesting it is not a substrate for P-glycoprotein. Furthermore, it
exhibited potent in vivo anti-cancer activity and excellent
pharmacokinetic parameters. We further optimize the structure of the
compound and generated a new analog with much improved potency
(IC50 of 1 nM) to inhibit cancer cell growth (Figure 1). The new
compound also showed much better potency to inhibit tubulin
polymerization, cause cell cycle arrest, and inhibit in vivo tumor growth
as well. However, we did notice mouse weight lost during the treatment,
suggesting toxicity to the animals. We speculate that the lead optimization
may result in off target effect, i.e., the new compound is binding to other
proteins besides tubulin and cause toxicity. It seems that the structural
optimization might cause target changing of the lead compound, and the
new off target proteins may cause the toxicity. To investigate the toxicity,
we synthesized 4 structures which are very similar analogs to compound
A, and all the compounds showed similar in vitro activity to inhibit
cancer cell growth. These compounds will be tested in the animals to
correlate the toxicity to the structures, and elucidate the toxic moiety of
the compounds. We also synthesized a biotinylated compound A to
investigate the potential off target proteins that bind to the compounds,
and explore the toxic inducing factors. This analysis can help us
understand what structural characteristics lead to the target switching
phenomenon. Understanding the structural difference correlated to the
molecular targets will help us to design new analogs with reduced toxicity.

IC50 =0.2 μM to inhibit cancer cell growth
Moderate tubulin inhibition

RESULTS

Cell Culture and MTT Assay
■ A172 and U373 brain cancer cell lines were maintained in DMEM
media containing cipro, FBS and penicillin streptomycin.
■ Cells grown in 96-well plates for 24 h.
■ Cells then treated with various agents' concentrations for 48 h.
■MTT Assay assessed for the cell lines.
■The final absorbance reading recorded at 570 nm using plate reader.
■ Determination of IC50 values using Graph Pad and normalize the
data by nonlinear regression analysis.

Design and synthesis of compound A biotinylated probe

CONCLUSIONS AND FUTURE
DIRECTIONS
Synthesis scheme

Results of MTT assay suggest that the four synthesized compounds
showed different activity to U373 and A172 cells, suggesting they may
target different pathways within these cells. The activity of four
compounds in A172 cells are in a similar range, indicating that their
tubulin targeting potency is similar. The in vivo toxicity of these
compounds is hypothesized to have an off target effect, which is the
future work.
Future experiments will be conducted to perform the in vivo toxicity
study and protein pull down assay to identify the off target proteins.
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